Rigel Pharmaceuticals (RIGL) Total Liabilities (2010 - 2026)

Rigel Pharmaceuticals has reported Total Liabilities for 17 years, with the latest figure at $104.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 33.48% year-over-year to $104.7 million; the trailing twelve-month figure through Mar 2026 stood at $104.7 million (down 33.48% YoY), and the FY2025 full-year result was $122.1 million, down 24.01% from the prior year.
• Total Liabilities for Q1 2026 stood at $104.7 million, down from $122.1 million in the prior quarter.
• The five-year high for Total Liabilities was $160.7 million in Q4 2024, with the low at $104.7 million in Q1 2026.
• Average Total Liabilities over 5 years is $141.7 million, with a median of $145.9 million recorded in 2023.
• Year-over-year, Total Liabilities increased 10.27% in 2023 and sank 33.48% in 2026.
• Tracing RIGL's Total Liabilities over 5 years: stood at $147.9 million in 2022, then slipped by 1.37% to $145.9 million in 2023, then rose by 10.16% to $160.7 million in 2024, then slipped by 24.01% to $122.1 million in 2025, then slipped by 14.25% to $104.7 million in 2026.
• The last three Total Liabilities figures came in at $104.7 million (Q1 2026), $122.1 million (Q4 2025), and $124.9 million (Q3 2025), per Business Quant data.

Peer Comparison